The big question for OB/GYNs, emergency department (ED) physicians, and the reproductive healthcare community is whether the U.S. Supreme Court’s decision on June 27, 2024, in the case of Idaho and Moyle v. United States, will change emergency care for pregnant women in the United States.
Researchers have released positive results from a Phase II study of Nestorone/testosterone (NES/T) transdermal gel, the first male contraception method to progress to Phase II clinical trials.
Reproductive health patients often describe having unpleasant symptoms related to their menstrual cycle. Premenstrual syndrome, for example, refers to any mood symptoms in the days or weeks before their period begins.
Separating preconception and contraceptive counseling between OB/GYNs and patients burdens patients and fractures reproductive healthcare. A better solution is to look at pregnancy planning, pregnancy prevention, and risk evaluation holistically.
As Opill, the first over-the-counter (OTC) oral birth control pill to be approved by the Food and Drug Administration (FDA), makes its way to grocery stores and pharmacies across the country, its usefulness remains a question mark for many young people.
When Americans think of medication abortion, they typically refer to the medication regimen of mifepristone and misoprostol, which together have been shown to be highly effective and safe.
